PR Newswire Clinical TrialsOriginal article
Altesa BioSciences Announces Upcoming Oral Presentation Featuring Novel Vapendavir Data at European Respiratory Society International Congress 2026
ConferencevapendavirPositive
AI Analysis
Summary
Altesa BioSciences announced an upcoming oral presentation of novel vapendavir data at the European Respiratory Society International Congress 2026, with results showing the drug reduces inflammatory biomarkers in COPD patients.
Outcome Details
Novel vapendavir data showing reduced inflammatory biomarkers in COPD patients to be presented
Importance:3/10
Sentiment:
0.30
respiratoryCOPDclinical-stagedata presentationERS Congress
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 7, 2026 11:00 AM